Bukwang Pharm Co Ltd
KRX:003000
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bukwang Pharm Co Ltd
Total Other Income
Bukwang Pharm Co Ltd
Total Other Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Other Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bukwang Pharm Co Ltd
KRX:003000
|
Total Other Income
₩409.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
|
|
Yuhan Corp
KRX:000100
|
Total Other Income
-₩6.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Total Other Income
-₩4.4B
|
CAGR 3-Years
-161%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Total Other Income
-₩38B
|
CAGR 3-Years
-76%
|
CAGR 5-Years
-65%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Total Other Income
₩147m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Total Other Income
₩335.3m
|
CAGR 3-Years
109%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
Bukwang Pharm Co Ltd
Glance View
Bukwang Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The firm operates its business through two segments. The Medicines and Quasi-drugs segment mainly produces and distributes pharmaceutical products including antidiabetic agents, anemic medicines, thyroid parathyroid hormone drugs, antihistamines, epileptic drugs, bronchodilators, stomatitis drugs, anti-malignant tumors, gum nutrition, hepatitis treatments, targeted anticancer agents, and others. The Research and Development segment mainly researches and develops pharmaceutical products.
See Also
What is Bukwang Pharm Co Ltd's Total Other Income?
Total Other Income
409.7m
KRW
Based on the financial report for Dec 31, 2025, Bukwang Pharm Co Ltd's Total Other Income amounts to 409.7m KRW.
What is Bukwang Pharm Co Ltd's Total Other Income growth rate?
Total Other Income CAGR 10Y
0%
